文献速递冠心病瓣膜病与结构性心脏病

内皮素-1基因失调与冠状动脉微血管功能障碍相关

Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction.
PubMed 文献 · Eur Heart J · 2020-01-01

rs9349379-G等位基因频率在CMD患者中高于参考基因组库(46% vs 39%,P=0.013),且与较高血浆ET-1水平及CMD风险增加相关(OR 2.33,95%CI 1.10-4.96,P=0.027)。非侵入性检查也显示G等位基因与心肌灌注及运动试验异常相关。

要点

  • rs9349379-G等位基因与CMD风险增加相关(OR 2.33)
  • G等位基因携带者血浆ET-1水平更高
  • ETA拮抗剂可逆转ET-1诱导的血管收缩,提示精准治疗可能

核心结论

  • rs9349379-G等位基因是CMD的新遗传风险位点,与ET-1水平升高及CMD风险增加相关。

主要发现

  • rs9349379-G等位基因频率在CMD患者中为46%(129/280),高于参考基因组库的39%(5551/14380),P=0.013。
  • G等位基因与较高血浆ET-1相关(最小二乘均值1.59 pg/mL vs 1.28 pg/mL;95%CI 0.10-0.53;P=0.005)。
  • G等位基因携带者CMD风险增加(OR 2.33,95%CI 1.10-4.96,P=0.027)。
  • 负荷心脏磁共振(N=107)显示G等位基因与心肌灌注异常相关(GG 56%,AG 43%,AA 31%,P=0.042)。
  • 运动试验(N=87)显示G等位基因与Duke运动平板评分降低3.0单位相关(95%CI -5.8至-0.1,P=0.045)。

关键数值与推荐

  • 离体血管张力测定显示G等位基因携带者外周小血管对ET-1反应保留,ETA拮抗剂高亲和力,zibotentan独立于G等位基因状态逆转ET-1诱导的血管收缩。

临床怎么用

  • 对于无阻塞性CAD的心绞痛患者,可考虑检测rs9349379-G等位基因以评估CMD遗传风险。
  • G等位基因携带者血浆ET-1较高,可能从口服ETA拮抗剂治疗中获益,支持精准医学策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Endothelin-1 (ET-1) is a potent vasoconstrictor peptide linked to vascular diseases through a common intronic gene enhancer [(rs9349379-G allele), chromosome 6 (PHACTR1/EDN1)]. We performed a multimodality investigation into the role of ET-1 and this gene variant in the pathogenesis of coronary microvascular dysfunction (CMD) in patients with symptoms and/or signs of ischaemia but no obstructive coronary artery disease (CAD). METHODS AND RESULTS: Three hundred and ninety-one patients with angina were enrolled. Of these, 206 (53%) with obstructive CAD were excluded leaving 185 (47%) eligible. One hundred and nine (72%) of 151 subjects who underwent invasive testing had objective evidence of CMD (COVADIS criteria). rs9349379-G allele frequency was greater than in contemporary reference genome bank control subjects [allele frequency 46% (129/280 alleles) vs. 39% (5551/14380); P = 0.013]. The G allele was associated with higher plasma serum ET-1 [least squares mean 1.59 pg/mL vs. 1.28 pg/mL; 95% confidence interval (CI) 0.10-0.53; P = 0.005]. Patients with rs9349379-G allele had over double the odds of CMD [odds ratio (OR) 2.33, 95% CI 1.10-4.96; P = 0.027]. Multimodality non-invasive testing confirmed the G allele was associated with linked impairments in myocardial perfusion on stress cardiac magnetic resonance imaging at 1.5 T (N = 107; GG 56%, AG 43%, AA 31%, P = 0.042) and exercise testing (N = 87; -3.0 units in Duke Exercise Treadmill Score; -5.8 to -0.1; P = 0.045). Endothelin-1 related vascular mechanisms were assessed ex vivo using wire myography with endothelin A receptor (ETA) antagonists including zibotentan. Subjects with rs9349379-G allele had preserved peripheral small vessel reactivity to ET-1 with high affinity of ETA antagonists. Zibotentan reversed ET-1-induced vasoconstriction independently of G allele status. CONCLUSION: We identify a novel genetic risk locus for CMD. These findings implicate ET-1 dysregulation and support the possibility of precision medicine using genetics to target oral ETA antagonist therapy in patients with microvascular angina. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03193294.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ford TJ, Corcoran D, Padmanabhan S, et al. Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. Eur Heart J. 2020. PMID: 31972008. doi:10.1093/eurheartj/ehz915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。